Bayer, Orion initiate Phase III trial of ODM-201 in non-metastatic CRPC

According to a media release today from Bayer HealthCare and Orion Corporation (a Finnish pharmaceutical company), they have started to  enroll patients in a randomized Phase III clinical trial of ODM-201, a novel, oral androgen receptor inhibitor in development for the treatment of men with advanced forms of prostate cancer. … READ MORE …

Mortality, body mass index, and Gleason score: the relationship

New data appear to suggest that you really don’t want to be diagnosed with high-risk prostate cancer if you are significantly over-weight or obese. … READ MORE …

Development of prostate cancer “organoids” may facilitate next-gen research

Researchers at Weill Medical College and at Memorial Sloan-Kettering Cancer Center in New York have worked out how to grow “organoids” from metastatic prostate cancer tissue. This may be important for the clinical testing of new types of treatment and (later on) for the ability to determine which drugs work well in individual patients. … READ MORE …

Educating newly diagnosed men about their prostate cancer before treatment

There is a short but simply outstanding article in this month’s issue of ASCO Connection by Anne Katz — a specialized oncology nurse who works up in Winnipeg, Manitoba. It deals with the conversations she has, often several times a day, with newly diagnosed prostate cancer patients at her institution. … READ MORE …

Do you have Stage IV or metastatic prostate cancer?

We understand that Health Monitor magazine is looking for a few men with Stage IV or metastatic prostate cancer (and possibly their spouses/partners) who are willing to be professionally interviewed. The magazine has a tight timeline. … READ MORE …

When is active surveillance not really active surveillance?

A story that got wide coverage yesterday (in the cancer-specific media, at least) said that “research published online in the Journal of Clinical Oncology suggests that ‘active surveillance for clinical stage I (CSI) testicular cancer leads to excellent outcomes’.” … READ MORE …

The costs of new treatments for cancer: the economics of reality

As regular readers will be aware, The “New” Prostate Cancer InfoLink regularly notes that the continuing rise in the prices of new drugs for the treatment of prostate cancer (and many other conditions too) is unsustainable. And what we need to do about it is hard to work out. … READ MORE …

Follow

Get every new post delivered to your Inbox.

Join 1,144 other followers